You can scoop up these top stocks for less than $50 a share.
News & Analysis: Pfizer
Bad news for AstraZeneca and CureVac should mean more good news for Pfizer and Moderna.
Efficacy against variants is showing the drug is the gold standard in preventing COVID.
The news continued to be good for mRNA vaccines.
The big drugmaker's bottom line won't be helped, but millions of people across the world will.
It's way too early to worry.
There's a pretty good case to be made that it is.
We may see the impact a year from now.
Looking for some extra income in this market? Consider these two blue-chip stocks.
It has to do with getting a step ahead of the coronavirus.